Pursuing Sinus Rhythm in Patients With Persistent Atrial Fibrillation. When Is It Too Late?

Journal of the American College of Cardiology

Volumn 54, Issue 9, 2009, Pages 796-798

  Wilber, David J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; catheter ablation; predictor

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVERSION; CATHETER ABLATION; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SINUS RHYTHM; STROKE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68649089265     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.073     Document Type: Editorial

References (34)

1. Petersen P., and Godtfredsen J. Embolic complications of paroxysmal atrial fibrillation. Stroke 17 (1986) 622-626
2. Kato T., Yamashita T., Sagara K., Iinuma H., and Fu L.T. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J 68 (2004) 568-572
3. Kerr C.R., Humphries K.H., Talajic M., et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 149 (2005) 489-496
4. Ruigomez A., Johansson S., Wallander M.A., and Garcia Rodriguez L.A. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Dis 5 (2005) 20-28
5. Tsang T.S., Barnes M.E., Miyasaka Y., et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 29 (2008) 2227-2233
6. Nieuwlaat R., Prins M.H., Le Heuzey J.Y., et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 29 (2008) 1181-1189
7. Hohnloser S.H., Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 356 (2000) 1789-1794
8. Van Gelder I.C., Hagens V.E., Bosker H.A., et al., Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
9. Carlsson J., Miketic S., Windeler J., et al., STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 (2003) 1690-1696
10. Singh B.N., Singh S.N., Reda D.J., et al., Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
11. Van Gelder I., Crijns H.J.G., Tieleman R.G., et al. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 156 (1996) 2585-2592
12. Allessie M., Ausuma J., and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54 (2002) 230-246
13. Burstein B., and Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51 (2008) 802-809
14. Lin C.S., and Pan C.H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65 (2008) 1489-1508
15. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
16. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
17. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003) 2920-2925
18. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
19. Corley S.D., Epstein A.E., DiMarco J.P., et al., AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 (2004) 1509-1513
20. Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003) 185-197
21. Nademanee K., Schwab M.C., Kosar E.M., et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 51 (2008) 843-849
22. Haïssaguerre M., Sanders P., Hocini M., et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 16 (2005) 1125-1137
23. Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354 (2006) 934-941
24. Fassini G., Riva S., Chiodelli R., et al. Left mitral isthmus ablation associated with PV isolation: long-term results of a prospective randomized study. J Cardiovasc Electrophysiol 6 (2005) 1150-1156
25. Willems S., Klemm H., Rostock T., et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J 27 (2006) 2871-2878
26. Elayi C.S., Verma A., Di Biase L., et al. Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies. Heart Rhythm 5 (2008) 1658-1664
27. Knecht S., Hocini M., Wright M., et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J 29 (2008) 2359-2366
28. Matsuo S., Lellouche N., Wright M., et al. Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. J Am Coll Cardiol 54 (2009) 788-795
29. Holm M., Pehrson S., Ingemansson M., et al. Non-invasive assessment of the atrial cycle length during atrial fibrillation in man: introducing, validating and illustrating a new ECG method. Cardiovasc Res 38 (1998) 69-81
30. Holmqvist F., Stridh M., Waktare J.E., et al. Atrial fibrillation signal organization predicts sinus rhythm maintenance in patients undergoing cardioversion of atrial fibrillation. Europace 8 (2006) 559-565
31. Sanchez-Quinones J., Marin F., Roldan V., and Lip G.Y. The impact of statin use on atrial fibrillation. QJM 101 (2008) 845-861
32. Makkar K.M., Sanoski C.A., and Spinler S.A. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 29 (2009) 31-48
33. Liu T., Li G., Li L., and Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49 (2007) 1642-1648
34. Oakes R.S., Badger T.J., Kholmovski E.G., et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119 (2009) 1758-1767